MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
192.43%
Quick Ratio
187.42%
Cash Ratio
118.66%
Debt to Asset Ratio
205.26%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Accounts receivable, net
    • Inventory, non-current
    • Others
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Revenue interest financing liabi...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
182,478
180,904
129,972
135,156
Prepaid expenses and other current assets
8,302
8,435
15,353
13,227
Accounts receivable, net
97,422
80,724
78,129
55,789
Inventory
7,713
6,508
5,518
3,611
Total current assets
295,915
276,571
228,972
207,783
Total property and equipment, gross
-
-
4,539
-
Less accumulated depreciation and amortization
-
-
3,475
-
Property and equipment, net
971
1,016
1,064
1,156
Operating lease right-of-use assets
2,410
2,508
2,603
2,694
Restricted cash
2,864
2,861
2,861
2,862
Inventory, non-current
21,827
19,076
20,732
24,101
Other long-term assets
3,088
3,088
2,917
1,693
Total assets
327,075
305,120
259,149
240,289
Accounts payable
5,361
6,365
4,983
1,075
Accrued expenses
109,027
83,317
89,831
65,349
Accrued interest
1,436
1,676
1,833
1,764
Operating lease liabilities, current
670
667
648
591
Current portion of revenue interest financing liability
37,283
33,016
27,249
24,344
Other current liabilities
-
-
7,500
-
Total current liabilities
153,777
125,041
132,044
93,123
Long-term debt, net of discount
164,587
163,675
209,087
207,093
Revenue interest financing liability
347,629
347,898
350,122
348,984
Operating lease liabilities
1,855
1,961
2,065
2,123
Other long-term liabilities
3,500
3,500
4,000
11,500
Total liabilities
671,348
642,075
697,318
662,823
Common stock, 0.0001 par value authorized shares -400,000,000 at june 30, 2026 and december 31, 2025 issued and outstanding shares - 80,070,048 and 71,419,025 at june 30, 2026 and december 31, 2025, respectively
8
7
6
6
Treasury stock -19 shares at june 30, 2026 and december 31, 2025
0
0
0
0
Additional paid-in capital
1,187,928
1,177,665
1,046,083
1,040,570
Accumulated deficit
-1,532,209
-1,514,627
-1,484,258
-1,463,110
Total stockholders' deficit
-344,273
-336,955
-438,169
-422,534
Total liabilities and stockholders' deficit
327,075
305,120
259,149
240,289
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$182,478K (22.00%↑ Y/Y)Accounts receivable, net$97,422K (90.07%↑ Y/Y)Prepaid expenses andother current assets$8,302K (-43.21%↓ Y/Y)Inventory$7,713K (124.80%↑ Y/Y)Total current assets$295,915K (35.20%↑ Y/Y)Inventory, non-current$21,827K (-11.54%↓ Y/Y)Other long-termassets$3,088K (82.40%↑ Y/Y)Restricted cash$2,864K (0.07%↑ Y/Y)Operating leaseright-of-use assets$2,410K (176.06%↑ Y/Y)Property and equipment,net$971K (-21.82%↓ Y/Y)Total assets$327,075K (30.71%↑ Y/Y)Accumulated deficit-$1,532,209K (-6.91%↓ Y/Y)Total liabilities andstockholders' deficit$327,075K (30.71%↑ Y/Y)Total stockholders'deficit-$344,273K (15.17%↑ Y/Y)Additional paid-in capital$1,187,928K (15.64%↑ Y/Y)Common stock, 0.0001par value...$8K (33.33%↑ Y/Y)Total liabilities$671,348K (2.33%↑ Y/Y)Revenue interestfinancing liability$347,629K (0.18%↑ Y/Y)Long-term debt, net ofdiscount$164,587K (-19.77%↓ Y/Y)Total currentliabilities$153,777K (67.47%↑ Y/Y)Other long-termliabilities$3,500K (-69.57%↓ Y/Y)Operating leaseliabilities$1,855K (214.94%↑ Y/Y)Accrued expenses$109,027K (69.57%↑ Y/Y)Current portion ofrevenue interest...$37,283K (73.20%↑ Y/Y)Accounts payable$5,361K (33.76%↑ Y/Y)Accrued interest$1,436K (-18.18%↓ Y/Y)Operating leaseliabilities, current$670K (181.51%↑ Y/Y)

Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc. (PHAT)